AstraZeneca Joins Pharma Investment Push in U.S. Amid Tariff Threat
The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.
The U.K.-based drugmaker plans to invest $50 billion in the United States as the industry seeks to appease President Trump.
